Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015', provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 8 Global Markets Direct Report Coverage 8 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview 9 Therapeutics Development 10 Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Overview 10 Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis 11 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Development by Companies 12 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 17 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Development by Companies 21 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Investigation by Universities/Institutes 25 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Companies Involved in Therapeutics Development 26 Absynth Biologics Limited 26 Actelion Ltd 27 ActogeniX NV 28 Adenium Biotech ApS 29 AIMM Therapeutics B.V. 30 Akthelia pharmaceuticals ehf 31 AmpliPhi Biosciences Corporation 32 Assembly Biosciences, Inc. 33 AvidBiotics Corp. 34 C3 Jian, Inc 35 Daiichi Sankyo Company, Limited 36 Evec, Inc. 37 GangaGen Inc. 38 ImmunoBiology Ltd. 39 Immuron Limited 40 Inovio Pharmaceuticals, Inc. 41 MedImmune, LLC 42 Merck & Co., Inc. 43 MGB Biopharma Limited 44 Microbiotix, Inc. 45 Micropharm Ltd 46 Nanotherapeutics, Inc. 47 Novabiotics Ltd 48 Oragenics, Inc. 49 Pfizer Inc. 50 Procarta Biosystems Ltd 51 Prokarium Ltd. 52 Sanofi Pasteur SA 53 Sarum Biosciences Limited 54 Sequella, Inc. 55 Shire Plc 56 Sorrento Therapeutics, Inc. 57 Stellar Biotechnologies, Inc. 58 Summit Therapeutics plc. 59 Synthetic Biologics, Inc. 60 Valneva SE 61 VaxInnate Corporation 62 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Combination Products 64 Assessment by Target 65 Assessment by Mechanism of Action 67 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 (actoxumab + bezlotoxumab) - Drug Profile 73 actoxumab - Drug Profile 74 AKT-10081 - Drug Profile 75 AmpliPHAGE-004 - Drug Profile 76 Antibodies for Enterocolitis - Drug Profile 77 AP-114 - Drug Profile 78 bezlotoxumab - Drug Profile 79 Biologic for Clostridium Difficile Enteropathy - Drug Profile 80 Biologic for Clostridium difficile Infections - Drug Profile 81 cadazolid - Drug Profile 82 Cdiff snare - Drug Profile 83 clostridium difficile vaccine - Drug Profile 84 Clostridium difficile vaccine - Drug Profile 85 clostridium difficile vaccine - Drug Profile 86 Clostridium difficile vaccine - Drug Profile 87 clostridium difficile vaccine - Drug Profile 88 Clostridium difficile vaccine - Drug Profile 89 Clostridium difficile vaccine - Drug Profile 90 Clostridium difficile vaccine - Drug Profile 92 clostridium difficile vaccine - Drug Profile 93 CRS-3123 - Drug Profile 94 Drug for Clostridium difficile Infection - Drug Profile 95 Endolysin - Drug Profile 96 EV-029104 - Drug Profile 98 EV-029105A - Drug Profile 99 fidaxomicin - Drug Profile 100 GBV-003 - Drug Profile 103 GBV-006 - Drug Profile 104 GN snare - Drug Profile 105 IMM-529 - Drug Profile 106 INS-001 - Drug Profile 107 INX-201 - Drug Profile 108 MB-101 - Drug Profile 109 MBX-500 - Drug Profile 110 MGBBP-3 - Drug Profile 111 Monoclonal Antibodies for Clostridium difficile - Drug Profile 113 Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile 114 Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile 115 Monoclonal Antibody to Inhibit Toxin A for Clostridium Difficile Infections - Drug Profile 116 MU-1140 - Drug Profile 117 NP-432 - Drug Profile 119 OraCAb - Drug Profile 120 P-4A - Drug Profile 121 PF-06425090 - Drug Profile 122 PolyCAb - Drug Profile 123 PRO-391 - Drug Profile 124 ramoplanin - Drug Profile 125 RBX-2660 - Drug Profile 126 Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile 127 SER-109 - Drug Profile 128 SER-262 - Drug Profile 129 Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile 130 Small Molecules for Clostridium Difficile Infections - Drug Profile 131 Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 132 Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile 134 SMT-19969 - Drug Profile 135 SMT-21829 - Drug Profile 137 SQ-109 - Drug Profile 138 SQ-641 - Drug Profile 141 surotomycin - Drug Profile 142 SYN-004 - Drug Profile 143 Synthetic Peptide for Clostridium difficile Infections - Drug Profile 144 VAL-301 - Drug Profile 145 VLA-84 - Drug Profile 147 VP-20621 - Drug Profile 149 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Recent Pipeline Updates 150 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects 177 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products 179 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Product Development Milestones 180 Featured News & Press Releases 180 Appendix 189 Methodology 189 Coverage 189 Secondary Research 189 Primary Research 189 Expert Panel Validation 189 Contact Us 189 Disclaimer 190
List of Tables
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H1 2015 14 Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H1 2015 15 Number of Products under Development by Companies, H1 2015 17 Number of Products under Development by Companies, H1 2015 (Contd..1) 18 Number of Products under Development by Companies, H1 2015 (Contd..2) 19 Number of Products under Development by Companies, H1 2015 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2015 29 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H1 2015 30 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2015 31 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ActogeniX NV, H1 2015 32 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H1 2015 33 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H1 2015 34 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Akthelia pharmaceuticals ehf, H1 2015 35 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H1 2015 36 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H1 2015 37 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AvidBiotics Corp., H1 2015 38 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by C3 Jian, Inc, H1 2015 39 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 40 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Evec, Inc., H1 2015 41 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by GangaGen Inc., H1 2015 42 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ImmunoBiology Ltd., H1 2015 43 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Immuron Limited, H1 2015 44 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 45 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MedImmune, LLC, H1 2015 46 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Merck & Co., Inc., H1 2015 47 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H1 2015 48 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Microbiotix, Inc., H1 2015 49 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2015 50 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H1 2015 51 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2015 52 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Oragenics, Inc., H1 2015 53 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Pfizer Inc., H1 2015 54 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Procarta Biosystems Ltd, H1 2015 55 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Prokarium Ltd., H1 2015 56 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2015 57 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sarum Biosciences Limited, H1 2015 58 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sequella, Inc., H1 2015 59 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Shire Plc, H1 2015 60 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H1 2015 61 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H1 2015 62 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Summit Therapeutics plc., H1 2015 63 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H1 2015 64 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valneva SE, H1 2015 65 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by VaxInnate Corporation, H1 2015 66 Assessment by Monotherapy Products, H1 2015 67 Assessment by Combination Products, H1 2015 68 Number of Products by Stage and Target, H1 2015 70 Number of Products by Stage and Mechanism of Action, H1 2015 72 Number of Products by Stage and Route of Administration, H1 2015 74 Number of Products by Stage and Molecule Type, H1 2015 76 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H1 2015 154 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects, H1 2015 181 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects (Contd..1), H1 2015 182 Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products, H1 2015 183
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
